- Home
- SLN vs PSNYW Comparison
SLN vs PSNYW Comparison
Compare SLN & PSNYW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLN
- PSNYW
- Stock Information
- Founded
- SLN 1994
- PSNYW 2017
- Country
- SLN United Kingdom
- PSNYW Sweden
- Employees
- SLN N/A
- PSNYW 2515
- Industry
- SLN Biotechnology: Pharmaceutical Preparations
- PSNYW Auto Manufacturing
- Sector
- SLN Health Care
- PSNYW Consumer Discretionary
- Exchange
- SLN Nasdaq
- PSNYW Nasdaq
- Market Cap
- SLN 223.4M
- PSNYW 400.8M
- IPO Year
- SLN N/A
- PSNYW N/A
- Fundamental
- Price
- SLN $4.23
- PSNYW $0.19
- Analyst Decision
- SLN Buy
- PSNYW
- Analyst Count
- SLN 5
- PSNYW 0
- Target Price
- SLN $40.80
- PSNYW N/A
- AVG Volume (30 Days)
- SLN 282.3K
- PSNYW 79.7K
- Earning Date
- SLN 02-27-2025
- PSNYW 03-06-2025
- Dividend Yield
- SLN N/A
- PSNYW N/A
- EPS Growth
- SLN N/A
- PSNYW N/A
- EPS
- SLN N/A
- PSNYW N/A
- Revenue
- SLN $43,258,000.00
- PSNYW $2,046,740,000.00
- Revenue This Year
- SLN N/A
- PSNYW N/A
- Revenue Next Year
- SLN N/A
- PSNYW $77.28
- P/E Ratio
- SLN N/A
- PSNYW N/A
- Revenue Growth
- SLN 36.71
- PSNYW N/A
- 52 Week Low
- SLN $4.06
- PSNYW $0.09
- 52 Week High
- SLN $27.72
- PSNYW $0.61
- Technical
- Relative Strength Index (RSI)
- SLN 41.17
- PSNYW 46.99
- Support Level
- SLN $4.10
- PSNYW $0.18
- Resistance Level
- SLN $5.23
- PSNYW $0.22
- Average True Range (ATR)
- SLN 0.40
- PSNYW 0.02
- MACD
- SLN 0.06
- PSNYW -0.00
- Stochastic Oscillator
- SLN 33.90
- PSNYW 28.29
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.
About PSNYW Polestar Automotive Holding UK PLC Class C-1 ADS (ADW)
Polestar Automotive Holding UK PLC operates as an electric vehicle manufacturer. It engages in designing products that are engineered to excite consumers and drive change. Polestar defines market-leading standards in design, technology, and sustainability. Polestar was established as a premium electric car brand by Volvo Cars and Geely Holdings. Polestar has produced two electric performance cars namely Polestar 1 and Polestar 2. Geographically, it derives a majority of revenue from USA.